Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases

Anne-lie Ståhl1 · Karl Johansson1 · Maria Mossberg1 · Robin Kahn1 · Diana Karpman1

Received: 27 July 2017 / Revised: 16 September 2017 / Accepted: 19 September 2017 / Published online: 27 November 2017
© The Author(s) 2017. This article is an open access publication

Abstract Extracellular vesicles are cell-derived membrane particles ranging from 30 to 5,000 nm in size, including exosomes, microvesicles, and apoptotic bodies. They are released under physiological conditions, but also upon cellular activation, senescence, and apoptosis. They play an important role in intercellular communication. Their release may also maintain cellular integrity by ridding the cell of damaging substances. This review describes the biogenesis, uptake, and detection of extracellular vesicles in addition to the impact that they have on recipient cells, focusing on mechanisms important in the pathophysiology of kidney diseases, such as thrombosis, angiogenesis, tissue regeneration, immune modulation, and inflammation. In kidney diseases, extracellular vesicles may be utilized as biomarkers, as they are detected in both blood and urine. Furthermore, they may contribute to the pathophysiology of renal disease while also having beneficial effects associated with tissue repair. Because of their role in the promotion of thrombosis, inflammation, and immune-mediated disease, they could be the target of drug therapy, whereas their favorable effects could be utilized therapeutically in acute and chronic kidney injury.

Keywords Extracellular vesicles · Exosomes · Microvesicles · Kidney · Inflammation · Thrombosis

Introduction

Intercellular communication is essential for multicellular organisms and cells communicate by a variety of mechanisms such as direct cell–cell contact, transfer of secreted molecules or intercellular transfer of extracellular vesicles (EVs). EVs are membrane-bound vesicles released by cells under physiological and pathological conditions. As EVs circulate in the blood, they may act as shuttle vectors or signal transducers both locally and at a distance from their site of origin [1]. Another function of EVs is the removal of unwanted molecular material or cellular waste [2], conceivably as a means of maintaining cellular integrity.

Extracellular vesicles are subdivided into exosomes, microvesicles, and apoptotic bodies (Table 1). Exosomes are the smallest vesicles (30–100 nm) released by the fusion of multivesicular bodies containing intraluminal vesicles with the plasma membrane. Microvesicles are vesicular structures (0.1–1.0 μm) shed by outward blebbing of the plasma membrane. The largest EVs (1–5 μm) are apoptotic bodies that are formed during the late stages of apoptosis [5, 10]. These subtypes of extracellular vesicles differ in their mechanism of biogenesis, as described below. This review focuses mainly on exosomes and microvesicles. Certain studies have not specifically analyzed the subtype of vesicle, in which case we refer to the general term EVs.

Although microvesicles and exosomes are structurally similar, they differ in size, lipid composition, content, and cellular origin (Table 1). EVs may be shed, under physiological or pathological conditions, into the extracellular environment either constitutively or upon activation, hypoxia, oxidative stress, senescence or apoptosis [4]. The release of vesicles may be induced by the stimulation of purinergic receptors [11], by shear stress or apoptosis [12, 13] and by proinflammatory mediators [14] or thrombin [15]. In addition, bacterial
virulence factors, such as Shiga toxin and lipopolysaccharides [16] and uremic toxins [17] induce the release of EVs.

Microvesicles carry membrane-derived receptors, proteins, including cytokines, chemokines, proteins involved in cellular signaling and/or migration, lipids, carbohydrates, and genetic material including mRNA and microRNAs (miRNAs) [4]. Their contents depend on the parent cell, the microenvironment and on the triggers preceding their release [5, 18–21]. The transfer of these substances to recipient cells may affect the phenotype of the target cell. EVs transport combinations of multiple mediators and are therefore considered a more powerful means of intercellular communication than the transfer of single molecules. Circulating microvesicles are mainly of platelet, erythrocyte, leukocyte, and endothelial origin [22–25]. Urinary microvesicles originate mainly from podocytes, tubular cells, and epithelial cells lining the urogenital tract [2].

**Extracellular vesicle biogenesis and release**

Exosomes are the product of the fusion of a subset of late endosomes, called multivesicular bodies, with the plasma membrane releasing their contents including intraluminal vesicles (ILVs). Once extracellular, these vesicles are termed exosomes (Fig. 1) [3]. ILV formation is regulated via the endosomal sorting complex required for transport (ESCRT, four protein complexes that guide intracellular cargo) [26], and/or by non-ESCRT-related mechanisms, including tetraspanins [27] and membrane lipids [28].

Microvesicles are released from cells under physiological conditions, especially during cell growth [29]. Microvesicle shedding is increased when the cells are activated owing to cell injury, proinflammatory stimulants, hypoxia, oxidative stress or shear stress [30, 31]. Microvesicles are formed by outward protrusion or budding of the plasma membrane. This process is initiated by an increase in intracellular cytosolic calcium that activates calpain, a calcium-sensitive protease that detaches membrane proteins from the intracellular cytoskeleton [32], and gelsolin bound to actin filaments [33]. This leads to remodeling of the cytoskeleton, by cleaving the actin protein network, enabling blebbing to occur. Microvesicles are shed from plasma membrane micro-domains known as lipid rafts or caveolae domains [34]. The plasma membrane is composed of a lipid bilayer in which phosphatidylserine is located in the inner leaflet of the resting cell. The enzymes flippase, floppase, and scramblase control phospholipid asymmetry [35]. When the cell is activated, increased cytosolic calcium activates floppase (allowing lipid movement to the outer membrane) and scramblase (enabling bi-directional lipid movement), whereas flippase (allowing lipid movement to the inner membrane) is inactivated, resulting in flopping of negatively charged phosphatidylserine to the outer leaflet of the plasma membrane [20]. This process does not always occur, as some microvesicles do not expose phosphatidylserine on their outer leaflet (Fig. 1) [36]. The presence of phosphatidylserine on the outer leaflet is readily detected, as it binds annexin V.

Microvesicles may express a slightly different repertoire of surface receptors or cytoplasmic components compared with the parent cell owing to a selective process during shedding.

| Size | Origin | Mechanism of formation | Release | Time of release | Pathways | Lipid membrane composition | Content |
|------|--------|------------------------|---------|----------------|----------|---------------------------|---------|
| 30–100 nm | Intraluminal vesicles within multivesicular bodies | Fusion of multivesicular bodies with the plasma membrane | Constitutive and/or cellular activation | Ten minutes or more | ESCRT-dependent | Enriched in cholesterol and ceramide, expose phosphatidylserine, contain lipid rafts | Proteins, mRNA, miRNA, lipids |
| 100–1,000 nm | Plasma membrane and cellular content | Outward blebbing of the plasma membrane | Constitutive and/or cellular activation | Few seconds | Ca²⁺-dependent | Expose phosphatidylserine, enriched in cholesterol and diacylglycerol, contain lipid rafts | Proteins, mRNA, miRNA, lipids |
| 1–5 μm | Plasma membrane, cellular fragments | Cell shrinkage and programmed cell death | Apoptosis-related | – | – | – | – |

**ESCRT** endosomal sorting complex required for transport

**Table 1** Main characteristics of exosomes, microvesicles, and apoptotic bodies

| | Exosomes | Microvesicles | Apoptotic bodies | References |
|---|---|---|---|---|
| Size | 30–100 nm | 100–1,000 nm | 1–5 μm | [3] |
| Origin | Intraluminal vesicles within multivesicular bodies | Plasma membrane and cellular content | Plasma membrane, cellular fragments | [4] |
| Mechanism of formation | Fusion of multivesicular bodies with the plasma membrane | Outward blebbing of the plasma membrane | Cell shrinkage and programmed cell death | [5, 6] |
| Release | Constitutive and/or cellular activation | Constitutive and/or cellular activation | Apoptosis | [4] |
| Time of release | Ten minutes or more | Few seconds | – | [7, 8] |
| Pathways | ESCRT-dependent | Ca²⁺-dependent | Apoptosis-related | [3] |
| Lipid membrane composition | Enriched in cholesterol and ceramide, expose phosphatidylserine, contain lipid rafts | Expose phosphatidylserine, enriched in cholesterol and diacylglycerol, contain lipid rafts | – | [3, 9] |
| Content | Proteins, mRNA, miRNA, lipids | Proteins, mRNA, miRNA, lipids | Cell organelles, proteins, nuclear fractions, DNA, coding and noncoding RNA, lipids | [3] |
Similarly, microvesicles released from activated cells do not express the same surface receptors as microvesicles shed during apoptosis [19] or from resting cells. This was demonstrated in vasculitis patients, microvesicles in patient samples taken during the active phase exhibited more CD62E and CD62P than those taken during remission and control samples [37].

Clearance and uptake of extracellular vesicles

The quantity of EVs in the circulation reflects a balance between their generation and clearance. Microvesicles released into the circulation have a half-life of a couple of minutes to a few hours [38], during which they may be taken up by neighboring or distant cells. In humans undergoing cardiopulmonary bypass, transfusion or dobutamine-induced cardiac stress, elevated levels of circulating microvesicles were detected, but these returned to baseline levels within 15 min to ~6 h [39, 40]. Interestingly, clearance of microvesicles may depend on the cellular origin of the microvesicles as platelet-derived microvesicles were cleared sooner than microvesicles released from red blood cells [40].

There are various mechanisms for the cellular uptake of vesicles depending on the cargo of the vesicle, intercellular communication (e.g. receptor-ligand interactions) and the microenvironment of the cell. The most common mechanism is endocytosis, whereby the extracellular vesicle is engulfed by the recipient cell [38]. There are several mechanisms of endocytosis, such as clathrin-dependent or -independent, caveolin-mediated, macropinocytosis, phagocytosis and lipid raft-mediated [41]. Uptake of EVs seems to depend on the type of recipient cell, its physiological state, and recognition of ligands or receptors on the recipient cell and EVs [41]. For example, vesicles shed from platelets interact with monocytes [42] and endothelial cells [22], but not with neutrophils [42]. Likewise, exosomes exposing the tetraspanin–integrin complex were selectively taken up by endothelial and pancreatic cells [43].

Another mechanism for microvesicle uptake is fusion, whereby the microvesicles fuse with the membranes of the recipient cell and the content of the vesicle is released into
the cell. Platelets expressing P-selectin fuse with tissue-factor-rich monocyte-derived microvesicles, increasing the procoagulability of platelets [34]. Fusion efficiency is enhanced in an acidic microenvironment (Fig. 1) [44].

Detection

Extracellular vesicles are mostly detected in blood samples, but also in cerebrospinal fluid [45], urine [46], synovial fluid [47], bronchoalveolar lavage fluid [48], breast milk [49], bile [50], saliva [51], and uterine fluid [52], and the findings may reflect a process occurring on their cells of origin. Techniques for extracellular vesicle detection are listed in Table 2 and briefly described below. Given the heterogeneity of EVs the detection methods vary depending on which vesicle population is studied. The small size of exosomes demands a high sensitivity analysis method, including nanoparticle tracking analysis and electron microscopy [54, 57]. For the detection of microvesicles flow cytometry is the most common technique.

Flow cytometry

The flow cytometer detects microvesicles as small as 150 nm in diameter (depending on the sensitivity of the instrument). The principle of detection is based on vesicles passing through a laser beam. Modern flow cytometers may have many lasers and fluorescence detectors, which allow for labeling with multiple conjugated antibodies in the same sample [64]. Microvesicles may have phosphatidylserine on their outer membrane enabling the use of conjugated annexin V for their detection [65].

Although flow cytometry is widely used to detect microvesicles, it has some limitations. Flow cytometry does not detect the smallest microvesicles as individual events. Multiple microvesicles may be detected collectively as a single event, a phenomenon termed swarm detection (Table 2) [66]. In addition, small microvesicles may have a limited number of antibody binding sites, sterically restricting staining with multiple antibodies [65]. Thus, both the number of small microvesicles and their surface expression may be underestimated.

Transmission electron microscopy

The transmission electron microscope (TEM) visualizes small structures (limited to approximately 1 nm) because of the high resolution of the technique. Immune electron microscopy entails adding a conjugated antibody to detect a specific antigen in the sample [67]. Negative staining is performed when the surrounding medium is stained, leaving the vesicles unstained and the contrast clearly visualizes the vesicles.

Nanoparticle tracking analysis

Nanoparticle tracking analysis (NTA) examines EVs in the liquid phase using a laser beam that determines the size and concentration by filming the light scattering when the particles move under Brownian motion [54]. The technique detects vesicles with a size of 0.05–1 μm (modern instruments may lower the detection limit even further). NTA can be used in fluorescent mode, thus detecting labeled vesicles [54]. NTA with fluorescent mode provides both quantitative and qualitative information on the vesicles in suspension.

Extracellular vesicles in physiological and pathological processes

During physiological and pathological processes, EVs are released and partake in cellular communication affecting processes such as coagulation and thrombosis, angiogenesis, immune modulation and inflammation, which are discussed in the following sections.

Intercellular communication

Extracellular vesicles use various mechanisms to transfer information to recipient cells. They may bind to receptors on target cells, thereby transducing a signal, or transfer functional receptors, proteins, lipids, mRNA or miRNA from parent cells to recipient cells in which they may induce phenotypic changes.

Extracellular vesicles in cell signaling

Extracellular vesicles expose numerous signaling proteins and lipids on their surface and may thus bind to and stimulate target cells directly. For example, microvesicles from platelets exposing P-selectin were shown to bind to P-selectin glycoprotein ligand-1 (PSGL-1) on the surface of leukocytes, leading to leukocyte accumulation and aggregation [68]. During morphogenesis of multicellular organisms, shed microvesicles exposing the morphogen protein “wingless” bind to a family of G protein-coupled receptors called frizzled, thereby forming a gradient necessary for adequate tissue development [69]. Similarly, lymphocyte-derived microvesicles carrying the morphogen “hedgehog” may bind to its receptor on early hematopoietic stem cells and thereby induce differentiation into megakaryocytes [70].

Transfer of receptors

Extracellular vesicles can transfer functional receptors to target cells, allowing cell signaling in cells that originally lacked the receptor or enhancing the number of receptors. For
| Method                  | Detection limit | Quantitative | Qualitative | Advantages                                                                 | Limitations                                                                                          | Applicable to                                                                                     | Reference |
|------------------------|-----------------|--------------|-------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------|
| Flow cytometry         | 300 nm          | Yes          | Yes         | Easily available, single particle counting, offers multi-antibody labeling of vesicles | Requires skilled staff, swarm detection, limitations in sizing of microvesicles, can miss small vesicles | Exosomesa, microvesicles and apoptotic bodies                                                   | [53]      |
| Nanoparticle tracking analysis | 50 nm          | Yesb         | Yes         | Short sample preparation, high resolution, and size determination of vesicles | Limited use of fluorescence, photo-bleachingc, can miss larger vesicles                                | Exosomes and microvesicles                                                                       | [54]      |
| Dynamic light scattering | 5 nm            | No           | No          | Size determination of vesicles and good reproducibility                    | Does not measure morphology or composition of vesicles                                               | Exosomes, microvesicles, and apoptotic bodies                                                   | [55]      |
| Resisitive pulse sensing | 70 nm          | Yes          | No          | Is semi-quantitative and enables single vesicle detection                  | Does not measure morphology or composition of vesicles, risk of pore clogging                      | Exosomes, microvesicles, and apoptotic bodies                                                   | [56]      |
| Transmission electron microscopy | ~1 nm       | Yes          | No          | Multiple antibody labeling, high resolution, and structural analysis       | Labor-intensive, requires extensive sample preparation and skilled staff, morphological changes of vesicles during sample preparation | Exosomes, microvesicles, and apoptotic bodies                                                   | [57]      |
| Atomic force microscopy | <1 nm           | No           | No          | Relative size distribution of the vesicles, structural analysis, and high resolution | Extensive sample preparation, morphological changes of vesicles during sample preparation            | Exosomes, microvesicles, and apoptotic bodies                                                   | [58, 59] |
| Immunoblot             | N/A             | No           | Yes         | Vesicle content detection                                                | Requires larger quantities. Does not distinguish between exosomes, microvesicles or soluble antigens | Exosomes, microvesicles, and apoptotic bodies                                                   | [60]      |
| ELISA                  | N/A             | No           | Yes         | Vesicle content detection and quantification                              | Can only measure captured vesicles, and requires larger quantities. Does not distinguish between exosomes, microvesicles or soluble antigens | Exosomes, microvesicles, and apoptotic bodies                                                   | [61]      |
| Proteomics             | N/A             | No           | Yes         | Quantifiable proteomic analysis of vesicle content                         | Does not distinguish between exosomes, microvesicles or soluble antigens. Time-consuming            | Exosomes, microvesicles, and apoptotic bodies                                                   | [62]      |

N/A not applicable

a Owing to limitations in detectable size, analysis of exosomes by flow cytometry requires conjugation to beads with a bound specific antibody and can thus not be quantified or detect other exosomes not binding the antibody [63]

b Nanoparticle tracking analysis can be used for the quantification of small vesicles such as exosomes, but not for larger vesicles [54]

c Photo-bleaching is the process by which a fluorescent antibody fades rapidly
example, microvesicles exposing the kinin B1 receptor transferred a functional receptor to endothelial cells and to human embryonic kidney cells [71]. The transfer of adhesion molecules and receptors from platelets to hematopoietic or malignant cells via platelet-derived microvesicles modulated their adhesion capacity and engraftment [72, 73]. Furthermore, microvesicles released from aggressive glioma cells transferred the oncogenic epidermal growth factor receptor (EGFR) to tumor cells causing a propagation of oncogenic activity [74]. The C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4) are important for HIV-1 uptake by cells. Microvesicle-mediated transfer of CCR5 and CXCR4 enabled HIV-1 to be internalized in cells previously not susceptible to the virus [75, 76], suggesting that this might be a means of disseminating HIV infection.

**Transfer of proteins and lipids**

Extracellular vesicles transport proteins such as cytokines, chemokines, and growth factors to neighboring or distant cells, resulting in modulation of the target cell. In addition, EVs may transfer functional channels. Exosomes originating in murine kidney-collecting duct cells (mCCDC11) transfer functional aquaporin 2 (AQP2), increasing water transport in recipient cells [77] and can thus potentially be involved in intra-renal signaling downstream in the nephron. Upon release, EVs may shelter proteins that would otherwise be phagocytosed or neutralized in free form in plasma, thus protecting their content from the host response [22]. This mode of transport can also be utilized by bacterial and viral components to evade the host response [22, 78]. Bioactive lipids, such as sphingosine 1-phosphate and arachidonic acid, are also transported within microvesicles [79]. Lipids in platelet microvesicles can increase adhesion between endothelial cells and monocytes [80]; hence, microvesicles not only affect recipient cells, but also other cells in their microenvironment.

**Transfer of mRNA and microRNA**

Extracellular vesicles are enriched in mRNA and miRNA, which can be transferred horizontally to and translated in recipient cells, thereby changing the phenotype of the cell. For example, microvesicles shed by endothelial progenitor cells induced activation of quiescent endothelial cells and stimulated angiogenesis by transfer of mRNA [81]. Mesenchymal stem cell (MSC)-derived EVs transfer mRNAs, inducing transcription and proliferation of tubular epithelial cells after in vivo injury [82]. Exosomes may regulate mRNA levels in recipient cells by delivering functional miRNA, thus blocking translation [83–85]. Transfer of miRNA by urinary exosomes to tubular cells modulated their function, as exemplified by diminished ROMK1 potassium channel levels in human collecting duct cells [86]. Exosomal transfer of certain miRNAs between immune cells conferred both a proinflammatory and an anti-inflammatory effect in vitro and in mice following endotoxin administration [87]. Likewise, vesicles derived from endothelial progenitor cells contain mRNAs coding for inhibitors of the complement system and anti-apoptotic molecules, thereby inhibiting complement-induced apoptosis and complement deposition on mesangial cells [88]. Interestingly, horizontal transfer of genetic material and the changes seen in the target cells were even demonstrated between cells of different species [89].

**Protection against stress and cell death**

To what extent EVs contribute to homeostasis and cell survival by ridding cells of unwanted substances is unknown, but may explain why cells release vesicles into their surroundings. The presence of complement C5b-9 on shed microvesicles may preserve the integrity of the parent cells by elimination of complement and the risk of cytolysis [90]. EVs from healthy individuals contain active caspase-3 that was not found in the parental cells, suggesting that caspase-3 might have been removed from the cells to ensure survival [91]. Inhibition of microvesicle release from viable endothelial cells containing active caspase-3 triggered both apoptosis and detachment of the cells [92].

Intriguingly, dying cells release microvesicles bearing the adaptor protein Crkl during the early stages of apoptosis induced by the caspase 3 cascade. These microvesicles were isolated from glomeruli after injury and were shown to induce compensatory proliferation signaling in recipient cells [93, 94]. Taken together, release of microvesicles may rid the cell of toxic substances, but may also induce repair in neighboring cells.

**Coagulation and thrombosis**

Extracellular vesicles play an important role in coagulation, platelet aggregation, and thrombosis. Pro-thrombotic properties of microvesicles are primarily associated with exposure of negatively charged phosphatidylserine and tissue factor [95]. Phosphatidylserine on circulating platelet- and monocyte-derived microvesicles provides binding sites for the assembly of coagulation factors such as factor IXa, Va, Xa, and VIII followed by thrombin generation [96]. Phosphatidylserine is also present on exosomal membranes [9]. It not only facilitates formation of coagulation complexes, but also promotes tissue factor activity [97]. Tissue factor is normally encrypted, but may be exposed on microvesicles released from platelets, monocytes or endothelial cells [16, 34, 98] and form a complex with factor VII/VIIa, thereby activating the extrinsic pathway of coagulation.

Platelet-derived microvesicles have a significantly higher pro-coagulant activity compared with activated platelets most
probably because of their higher surface density of phosphatidylserine, factor Xa, P-selectin, and αIIbβ3 (glycoprotein IIb/IIIa) [99]. At the site of vascular injury, platelet-derived microvesicles support thrombus formation by facilitating the adhesion of platelets to endothelial cell matrix components [100]. The interaction between PSGL-1 on monocyte-derived microvesicles and selectins on platelets, endothelial cells or their shed microvesicles provides a basis for thrombus formation [34].

**Angiogenesis**

Microvesicles derived from blood and endothelial and tumor cells [101] may possess angiogenic properties, as previously reviewed [102]. The angiogenic effect may be associated with exposure of surface molecules or growth factors within the vesicles. Lymphoid microvesicles induced production of endothelial nitric oxide formation, expression of adhesion molecules, in addition to in vitro angiogenesis and in vivo neovascularization in endothelial cells [103]. Endothelial cell-derived microvesicles induced invasion of endothelial cells into basement membranes followed by capillary-like structure formation in vitro [104]. These properties may be of importance during tissue injury, post-ischemic revascularization and regeneration [105], and thus have importance during acute kidney injury (AKI).

**Immune modulation**

Extracellular vesicles play an important role in promoting immune responses, affecting both innate and adaptive immunity. Dendritic cell-derived exosomes enhanced the cytotoxic activity of natural killer cells [106]. Moreover, dendritic cell microvesicles stimulated epithelial cells to release pro-inflammatory cytokines [107], leukocyte-derived microvesicles activated the endothelium, upregulating adhesion molecules and releasing cytokines, leading to leukocyte recruitment [108] and platelet microvesicles affected the adhesion of monocytes to the endothelium [80].

Extracellular vesicles may have antigen-presenting properties, exposing major histocompatibility complexes (MHCs). Dendritic cells stimulated with lipopolysaccharide shed vesicles exposing MHC II, CD83, and the co-stimulatory molecule CD40 on their surface initiating a pro-inflammatory response in epithelial cells and T-cell activation [107, 109]. Interestingly, dendritic microvesicles containing tumor necrosis factor-α could initiate an innate immune response in epithelial cells, leading to cytokine release without transfer of antigen-presenting properties [107]. Microvesicles may also affect adaptive immunity, as platelet-derived microvesicles can increase immunoglobulin production by B-cells [110].

Activation of the complement system is usually directed against foreign antigens such as bacteria or damaged host cells. Complement activation and deposition of the membrane attack complex on blood cells is followed by the release of complement-coated microvesicles [111, 112]. Microvesicles bearing C1q reflect activation of the classical pathway of complement on the parent cell [113], whereas the presence of C3 reflects amplification of all three pathways of the complement via the alternative pathway [111]. Direct activation on vesicles, after shedding, may potentially also occur. Blood cell-derived EVs expose complement regulators on their surface such as complement receptor type 1 (CR1), membrane cofactor protein (CD46), decay accelerating factor (DAF/CD55) or CD59 [111, 114], thereby inhibiting assembly of the membrane attack complex (C5b-9) and preventing excessive complement activation. In addition, EVs opsonized by C3b are rapidly cleared from the circulation by phagocytes [115].

**Malignancies**

Tumor cells release significant numbers of EVs [116] that may influence proliferation, migration, invasion, and immune escape of cancer cells as well as angiogenesis [117] and the tumor environment [118]. EVs may also prime distant organs to a pre-metastatic niche facilitating survival and growth of metastasis [119]. An important step in tumor development is inhibition of immune surveillance. Tumor-derived exosomes can suppress T-cell immunity [120], thereby contributing to tumor progression by modulating and preventing anti-tumor immune reactions. The topic of EVs in malignancies has been reviewed elsewhere [116, 121].

**Inflammation**

Extracellular vesicles are capable of inducing both inflammatory and anti-inflammatory responses. This may be associated with the transfer of pro- and anti-inflammatory mediators and by inducing the release of cytokines from target cells [108, 122–124]. Both leukocyte- and platelet-derived microvesicles induced cytokine release from endothelial cells [122, 125], suggesting that microvesicles might participate in vascular damage and inflammatory disorders. Moreover, EVs may induce chemotaxis. Platelet-derived microvesicles stimulated recruitment of hematopoietic cells [73] and promoted leukocyte migration [126]. Glomerular endothelial cell-derived microvesicles exposing the kinin B1 receptor and interleukin 8 (IL-8) on their surface attracted neutrophils [127, 128]. Proximal tubular cells cultured in the presence of fenoldopam (a dopamine receptor agonist) released exosomes that reduced the production of reactive oxygen species in distal tubule and collecting duct cells [129], indicating the transfer of an anti-inflammatory response.
Anti-microbial effects

Neutrophil-derived microvesicles have been demonstrated to possess antimicrobial properties with a bacteriostatic effect on the uropathogen *Escherichia coli* [130]. Urinary exosomes also possess antimicrobial peptides, inhibiting the growth of *E. coli* and inducing bacteriolysis [131]. It has also been postulated that tissue factor-bearing microvesicles may prevent bacteria in the urinary tract from spreading beyond the uroepithelial barrier [132].

Extracellular vesicles as biomarkers and promoters of kidney disease

The prothrombotic, proinflammatory, and immunomodulatory properties associated with EVs, described above, may all contribute to and maintain tissue damage in the kidney and urinary tract during the development of AKI, glomerular and tubular diseases, infections, and chronic renal failure in addition to numerous other conditions affecting the kidney. These aspects have been comprehensively reviewed recently by our group and others [2, 128, 133]. Studies on the role of EVs in AKI have mostly been carried out in patients with sepsis, burns or other forms of acute tubular injury [134, 135]. Our group has focused on the role of microvesicles in hemolytic uremic syndrome and vasculitis, which will be elaborated on below. In Table 3, we summarize various renal conditions in which EVs have been described as biomarkers of disease, in blood or urine, and describe which characteristics contribute to the induction and propagation of tissue injury.

Microvesicles in hemolytic uremic syndrome

Circulating microvesicles are elevated in thrombotic microangiopathies. Microvesicles derived from platelets, neutrophils, monocytes, and red blood cells were detected in blood samples from patients with Shiga toxin-producing *E. coli* (STEC)-associated hemolytic uremic syndrome (HUS) [16, 22, 23, 111, 219]. Patients with thrombotic thrombocytopenic purpura (TTP) exhibit elevated levels of both platelet and endothelial-derived microvesicles, the latter coated with complement deposits [162, 163, 220].

Our studies have shown that circulating microvesicles in STEC-HUS are pro-thrombotic/procoagulant as they are both tissue factor- and phosphatidylserine-positive. These aspects could be reproduced in vitro when whole blood was stimulated with Shiga toxin and *E. coli* O157 lipopolysaccharide and shed pro-thrombotic microvesicles were mainly derived from platelets [16]. Similarly, platelet- and monocyte-derived microvesicles in patient samples and in in vitro toxin-stimulated samples were coated with deposits of C3 and C9, suggesting ongoing complement activation.

Patients with STEC-HUS also exhibited elevated C3 and C9 on microvesicles derived from red blood cells, and, interestingly, Shiga toxin could induce complement activation on red blood cells followed by hemolysis, thereby releasing microvesicles from red blood cells with deposits of the membrane attack complex C5b-9 [23]. Shiga toxin is transported in vivo bound to blood cells and after uptake in these cells released within microvesicles (reviewed in Karpman et al. [221]). Blood cell-derived microvesicles transport Shiga toxin to the kidney, where the toxin, within microvesicles, is taken up in glomerular endothelial cells and peritubular capillary endothelial cells. Within the endothelial cells, the microvesicles either empty their cargo or are transcytosed through the cells, and their corresponding basement membranes, into podocytes or tubular cells, respectively. Eventually the microvesicles empty their cargo, although the signal leading to this release of contents is unknown. Intracellular toxin undergoes retrograde transport, binds to ribosomes and induces cell death thus causing renal failure [22]. HUS is characterized by platelet activation and the formation of microthrombi, hemolysis, and acute renal failure. These studies show that microvesicles are not only biomarkers, but actively contribute to disease-specific processes during STEC-HUS by creating a pro-thrombotic environment, partaking in hemolysis, and transporting Shiga toxin into the kidney to induce renal cell death.

In similarity to the pro-thrombotic microvesicles demonstrated in patients with STEC-HUS, serum from patients with aHUS, with mutations in the complement regulator factor H, induced the release of tissue factor- and phosphatidylserine-positive platelet-derived microvesicles from normal washed platelets, effects that could be inhibited by the addition of normal factor H [161].

Microvesicles in vasculitis and inflammatory disorders

Microvesicles shed from endothelial cells, platelets, and leukocytes were increased during the acute phase of vasculitis, returning to normal levels during remission [25, 37, 152]. Endothelial microvesicle levels in pediatric vasculitis correlated with the Birmingham Vasculitis Activity Score (BVAS), C-reactive protein, and erythrocyte sedimentation rate [165]. Likewise, endothelial microvesicles in adults with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) correlated with the BVAS [37] and could thus be used as a biomarker for disease activity [37, 165].

The ANCAs circulating in patients with AAV activated neutrophils, causing them to release microvesicles [167]. In patients with vasculitis, neutrophil microvesicles activated
| Renal disease          | Presence in bodily fluid or tissue | Type of extracellular vesicle | Cell of origin | Importance | Association with pathophysiology or beneficial effect | References |
|-----------------------|-----------------------------------|-------------------------------|---------------|------------|------------------------------------------------------|------------|
|                       |                                    |                               |               |            | Biomarker                                            | References |
| AKI/sepsis            | Blood                             | EV and MV                     | P, E, L       | +^b        | May induce proteinuria and renal failure             | [136–142] |
|                       |                                    |                               | P, E          |            | Induce vessel reactivity                             | [134, 135, 143] |
|                       |                                    |                               | E             |            | Proadhesive (PECAM-1, endoglin-positive) in association with DIC | [138] |
|                       |                                    |                               | E             |            | Levels of EVs correlate inversely with survival      | [140, 141] |
|                       | Bone marrow, blood, and tissue     | Ex and MV                     | P, L, RBC, E  | +          | Antimicrobial properties                             | [130, 144] |
|                       | Urine                             | Ex or EV                      | ns            | +^d        | EVs have regenerative properties during AKI          | [145–147] |
| CKD or ESRF           | Blood                             | EV                            | P, E          |            | Pro-thrombotic                                      | [17, 152–156] |
|                       |                                    |                               | E             |            | Correlate with vascular dysfunction                  | [153, 154] |
|                       |                                    |                               | P, N, M       |            | Predict cardiovascular disease                       | [158] |
| TMA                  | Urine                             | Ex                            | P, C3 and C9  | +^c        | Pro-thrombotic (TF- and PS-positive)                  | [16, 111] |
| STEC-HUS             | Blood                             | MV                            | P, RBC, P     |            | Partake in hemolysis                                | [23] |
|                       |                                    |                               | P, N, M       |            | Transfer Shiga toxin to the kidneys                  | [22] |
| aHUS                 | Blood                             | MV                            | P             |            | Pro-thrombotic (TF- and PS-positive)                 | [161] |
|                       |                                    | MV                            | P             |            | Associated with calpain activity                     | [162] |
|                       |                                    |                               | E, C3 and C9  |            | Pro-coagulant and proadhesive (VWF, CD62E, ICAM-1, PECAM-1, endoglin-positive) | [163, 164] |
| Vasculitis            | Blood                             | MV                            | P, N, E       | +^g        | P, N or ns                                          | [37, 165, 166] |
|                       |                                    |                               | N             | PS-, TF-, selectin-, integrin-, PR3- and MPO-positive | [167, 168] |
|                       |                                    |                               | N             | Pro-thrombotic                                      | [169, 170] |
|                       |                                    |                               | N             | Bind C1q   | [168] |
|                       | Blood and kidney                  |                               | N             | Activate endothelial cells and monocytes             | [167] |
|                       |                                    |                               | N             | Transfer the kinin B1 receptor to endothelial cells inducing inflammation | [71] |
| IgA nephropathy       | Blood                             | MV and Ex                     | RBC           | +^h        | Induce neutrophil chemotaxis                         | [127] |
| Nephrotic syndrome    | Urine                             | MV                            | E             |            | Pro-thrombotic (PS-positive)                         | [171–174] |
|                       |                                    |                               | E, M          |            | May contribute to albuminuria^i                      | [175] |
|                       | Urine                             | MV and Ex                     | Pod           | +^i        | [151, 176–180] |
### Table 3 (continued)

| Renal disease                | Presence in bodily fluid or tissue | Type of extracellular vesicle | Cell of origin | Importance                                                                 | References |
|------------------------------|-----------------------------------|------------------------------|----------------|----------------------------------------------------------------------------|------------|
| Urinary tract infection/urosepsis | Blood MV ns                       | ns                           | Pro-thrombotic (TF-positive) | [181]                  |            |
|                               | Urine Ex                          | +                            | Antimicrobial properties    | [131]                  |            |
| Urine EV +                    |                                   |                              |                             | [182, 183]             |            |
| Tubulopathies                 | Urine Ex                          | +                            | Aquaporin-2 and its response to vasopressin differ in NDI vs CDI | [185]                  |            |
| Bartter syndrome             | Urine Ex                          | +                            |                             | [184]                  |            |
| Gitelman syndrome            | Urine Ex                          | +                            |                             | [186]                  |            |
| Diabetes insipidus           | Urine EV ns                        | +                            |                             | [187]                  |            |
| ADPKD                        | Urine Ex                          | +                            | Inverse correlation of the polycystin-1 or polycystin-2/transmembrane 2 ratios with kidney volume | [188]                  |            |
| Hypertension                 | Blood EV P, E                      | +                            | Indicate vascular injury    | [189]                  |            |
|                              | MV E                               |                              | Elevated in patients with microalbuminuria | [190]                  |            |
|                              | EV E                               |                              |                             | [191]                  |            |
| Renal transplantation        | Urine EV ns +                     | +                            | TF activity decreases after transplantation | [192]                  |            |
|                              | MV P, L, RBC                       | +                            | Antigen-presenting vesicles activate anti-donor T cells | [193]                  |            |
|                              | Ex                                |                              |                             | [194]                  |            |
|                              | Ex E                               |                              |                             | [195]                  |            |
|                              | Ex MV P, E                         |                              | Transfer of CMV antigens    | [196, 197]             |            |
|                              | Urine MV CD133+ nephron-- derived | +                            | Treatment with ATG and calcineurin inhibitors induces the release of complement-coated MVs | [198]                  |            |
|                              | MV Ex                              | +                            | Delayed graft function and vascular injury | [199]                  |            |
|                              | Ex                                | +                            | NGAL marker of delayed graft function | [200, 201]             |            |
|                              | Ex                                | +                            | Decreased aquaporin 1 indicative of ischemia–reperfusion injury | [202]                  |            |
|                              | Ex                                | +                            |                             | [203]                  |            |
|                              | Kidney MV P                        | +                            | Platelets and platelet-derived MVs at sites of endothelial damage | [204, 205]             |            |
| SLE                          | Blood EV E or ns                   | +                            | Contribute to immune complex deposition and complement activation | [206]                  |            |
|                              | Urine MV P                         | +                            | Prothrombotic               | [207]                  |            |
| Renal disease       | Presence in bodily fluid or tissue | Type of extracellular vesicle | Cell of origin | Importance | Biomarker | Association with pathophysiology or beneficial effect | References |
|---------------------|------------------------------------|-------------------------------|----------------|------------|-----------|-------------------------------------------------------|------------|
| APS                 | Blood                              | MV                            | E              |            |           | Pro-thrombotic                                        | [208, 209] |
| Atherosclerosis     | Blood                              | MV                            | E, P, L        |            |           | Pro-thrombotic and proinflammatory                     | [210]      |
| Diabetes mellitus   | Blood                              | EV                            | A, I, M        | +          |           | Pro-thrombotic, proinflammatory, correlated with arterial stiffness | [211]      |
|                     | Urine                              | Ex                            |                |            | +         | Urinary exosomal regucalcin decreased in diabetic nephropathy | [216]      |

AKI acute kidney injury, EV extracellular vesicle, MV microvesicle, P platelet, E endothelial, L leukocyte, PECAM-1 platelet endothelial cell adhesion molecule (CD31), DIC disseminated intravascular coagulation, Ex exosome, ns not specified (for exosomes the distinction of the parent cell is not possible unless a specified cell type was studied), N neutrophil, MSC mesenchymal stem cells, M monocyte, RBC red blood cell, CKD chronic kidney disease, ESRF end-stage renal failure, TMA thrombotic microangiopathy, TF tissue factor, PS phosphatidyserine, PR3 proteinase 3, MPO myeloperoxidase, STEC-HUS Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome, aHUS atypical HUS, TTP thrombotic thrombocytopenic purpura, VWF von Willebrand factor, CD62E E-selectin, ICAM-1 intercellular adhesion molecule 1, ND1 nephrogenic diabetes insipidus (DI), C1q central DI, ADPKD autosomal dominant polycystic kidney disease, ATG antithymocyte globulin, SLE systemic lupus erythematosus, APS anti-phospholipid syndrome, A adipocytes, I islet cells

a Detected extracellular vesicles were not specified as exosomes, microvesicles or apoptotic bodies
b Elevated extracellular vesicles and miRNA may serve as biomarkers
c The exosomal fraction is responsible for the regenerative effects [146]
d Na/H exchanger isoform 3, fetuin-A or activating transcription factor 3 may reflect tubular injury
e miRNA profiles correlated with perturbed renal function and renal fibrosis
f Indicating complement activation
g Correspond to the Birmingham vasculitis activity score
h A miRNA profile derived from miRNA containing microvesicles. Protein biomarkers include α1-antitrypsin, aminopeptidase N, vasorin precursor, ceruloplasmin, and podocalyxin
i In vitro incubation of microvesicles with podocytes
j Urinary extracellular vesicle fractions contain nephrin, transient receptor potential cation channel 6, inverted formin-2 and phospholipase A2 receptor and Wilms tumor-1. In membranous nephropathy the microvesicles were positive for Lysosome Membrane Protein 2
k A distinct miRNA profile
l Higher in severe hypertension compared to mild hypertension
m Associated with renovascular hypertension and lower estimated glomerular filtration rate
n Levels decrease after renal transplantation (less so in patients with cardiovascular disease) and correlate inversely with renal function
o A proteomics approach determined patterns of rejection
p Levels correlate with SLE activity score, glomerulonephritis, hypertension, previous arterial thrombosis, and lipidemia
endothelial cells, leading to the release of cytokines [108, 122, 167]. Neutrophil microvesicles may expose proteinase 3 (PR3) and myeloperoxidase (MPO) on their surfaces enabling ANCA to bind. Microvesicles were pro-thrombotic as they promoted the generation of thrombin [167], and could thus contribute to the thromboembolic complications seen in vasculitis.

Our studies have demonstrated systemic activation of the kinin system in children and adults with vasculitis underlying the profound vascular inflammation [222, 223]. We have shown that neutrophil-derived microvesicles bearing the kinin B1 receptor, expressed on cells during chronic inflammation, can transfer the receptor to cells lacking the receptor (demonstrated using transfected and wild-type HEK cells) and to glomerular endothelial cells, thereby promoting the inflammatory response. The phenomenon was confirmed in kidney biopsies showing that B1-receptor-positive neutrophil-derived microvesicles dock on glomerular endothelial cells in vivo during vasculitis [71]. Furthermore, during extensive vascular injury, endothelial microvesicles are released, also bearing the B1 receptor [127]. The B1-receptor-positive endothelial microvesicles recruited neutrophils, thus enhancing the inflammation. Interestingly, C1 inhibitor, the main inhibitor of the kinin system, inhibited the release of the chemotactic glomerular endothelial microvesicles.

In systemic lupus erythematosus (SLE), platelet-derived microvesicles are significantly increased and correlate with thrombin generation, suggesting a role in the thromboembolic state [206]. Other aspects, such as the contribution to immune complex deposition, are presented in Table 3.

Antiphospholipid syndrome is an autoimmune disease associated with antiphospholipid antibodies and thrombotic complications. Patients with antiphospholipid syndrome have elevated endothelial and platelet-derived microvesicles compared with controls and the endothelial vesicles may be prothrombotic [208].

The effect of renal replacement therapy and drugs on extracellular vesicles

Treatments given during acute and chronic renal failure may affect levels of EVs. Dialysis treatment (hemodialysis and peritoneal dialysis) not only does not remove EVs, it may increase levels in comparison with healthy controls and after treatment sessions [17, 153]. The same is true for miRNA levels, which do not decrease after hemodialysis [136]. Treatment with recombinant erythropoietin may enhance levels of platelet-derived microvesicles, whereas the presence of an arteriovenous fistula has no effect on microvesicle levels [154].

To our knowledge, the effect of plasma exchange on levels of EVs has not been specifically addressed, but plasma exchange should presumably remove EVs. This has been suggested in the treatment of patients with SLE and antiphospholipid syndrome [224].

Various drugs used in the treatment of renal disease, including anti-hypertensive medications such as calcium channel blockers, amiloride, and beta blockers, or statins, may affect the release of EVs, as reviewed [128, 225]. Amiloride affects both the release and uptake of vesicles [226, 227].

The renal regenerative capacity of extracellular vesicles

Mesenchymal stem cells and endothelial progenitor cells secrete EVs that have been demonstrated to induce nephron regeneration and repair by inhibiting apoptosis and promoting tubular proliferation. These effects have been documented in vitro [228] and in vivo [229] and are attributed to the transfer of both growth factors and RNAs (mRNAs and miRNAs) [230]. As described above, EVs can stimulate angiogenesis, and transfer growth factors such as vascular endothelial growth factor, hepatocyte growth factor [231], insulin-like growth factor-1 (IGF-1), adrenomedullin, and stromal cell-derived factor-1 (SDF1) [4]. Horizontal transfer of the IGF-1 receptor mRNA transcript via MSC EVs to damaged tubular cells induced proliferation [232]. EVs derived from MSCs localize to the kidney [233] and have been extensively investigated, in preclinical studies, for their therapeutic potential to protect tubuli and repair ischemia/reperfusion-induced injury [234].

Extracellular vesicles as vehicles for drug delivery

The capacity of EVs to deliver proteins, lipids, and nucleic acids to recipient cells has therapeutic potential. EVs can be designed to target specific recipient cells. Cells can be genetically altered to express ligands on their membrane that are also present on EVs released from the cells. These ligands can bind to receptors on the target cell [235]. Thus, EVs can be loaded with therapeutic substances for delivery to target cells. These exciting developments in EV-based therapeutics may be used in future clinical trials and have been recently reviewed [236, 237].

Conclusions

Extracellular vesicles play an important role in normal intercellular communication. They can be detected as biomarkers of disease owing to their excessive numbers and
their properties and may also contribute to the development of diseases, including kidney disease, by inducing inflammation, vascular injury, and thrombosis in addition to modulating the immune response. Their contribution to the induction and progression of renal diseases may lead to the development of treatments geared toward temporary reduction of EVs systemically in the circulation, or locally in the kidney and urinary tract. Treatments that reduce the release or uptake of EVs need to take into account the notion that EVs may also be cytoprotective, as their release and the removal of unwanted or damaging substances from their parent cells may maintain cellular integrity. EVs may have potentially beneficial properties associated with tubular regeneration and the induction of angiogenesis. The therapeutic potential and nephroprotective effects of EVs, owing to their capacity to shuttle proteins, lipids, and genetic cargo to recipient cells, are being explored in preclinical studies, which may lead to clinical trials in the future.

Acknowledgements A portion of the text and figure appeared in the Ph.D. thesis (2017) by Dr Maria Mossberg.

Funding DK is supported by The Swedish Research Council (K2013-64X-14,008-13-5 and K2015-99X-22,877-01-6), The Knut and Alice Wallenberg Foundation (Wallenberg Clinical Scholar 2015.0320), The Torsten Söderberg Foundation, Skåne Centre of Excellence in Health, IngaBritt and Arne Lundberg Research Foundation, Crown Princess Lovisa’s Society for Child Care, Region Skåne, and The Konung GustafVs 80-års minnesfond. RK is supported by the Swedish Rheumatism Association, The Medical Faculty at Lund University, Alfred Österlund’s Foundation, The Anna-Greta Crafoord Foundation, Greta and Johan Kock Foundation, Samariten Foundation, Sven Jerring Foundation, The Crafoord Foundation, and the Thelma Zoegas Foundation.

Compliance with ethical standards Conflicts of interest The authors declare that they have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Mittelbrunn M, Sanchez-Madrid F (2012) Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol 13:328–335
2. Pomatto MAC, Gai C, Bussoleti B, Camussi G (2017) Extracellular vesicles in renal pathophysiology. Front Mol Biosci 4:37
3. Colombo M, Raposo G, Thery C (2014) Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30:255–289
4. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L (2010) Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78:838–848
5. Thery C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9:581–593
6. Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6:267–283
7. Zhang HG, Grizzle WE (2014) Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 184:28–41
8. Cocucci E, Meldolesi J (2015) Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol 25:364–372
9. Skotland T, Sandvig K, Llorente A (2017) Lipids in exosomes: current knowledge and the way forward. Prog Lipid Res 66:30–41
10. Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, Laszlo V, Pallinger E, Pap E, Kittel A, Nagy G, Falus A, Buzas EI (2011) Membrane vesicles, current-state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68:2667–2688
11. Wilson HL, Francis SE, Dower SK, Crossman DC (2004) Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J Immunol 173:1202–1208
12. Holme PA, Orvim U, Hamers MJ, Solum NO, Brossad FR, Barstad RM, Sakariassen KS (1997) Shear-induced platelet activation and platelet microparticle formation at blood flow conditions in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 17:646–653
13. Lynch SE, Ludlam CA (2007) Plasma microparticles and vascular disorders. Br J Haematol 137:36–48
14. Nomura S, Nakamura T, Cone J, Tandon NN, Kambayashi J (2000) Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation. Cytometry 40:173–181
15. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microparticles by surface shedding and exosomes derived from excocytosis of multivesicular bodies and alpha-granules. Blood 94:3791–3799
16. Ståhl AL, Sartz L, Nelsson A, Békássy ZD, Karpman D (2009) Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 109:175–180
17. Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. J Proteome 73:1907–1920
22. Stähl AL, Arvidsson I, Johansson KE, Chromek M, Rebetz J, Loos S, Kristofferson AC, Bekassy ZD, Mörkelin M, Karpman D (2015) A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog 11:e1004619
23. Arvidsson I, Stähl AL, Hedström MM, Kristofferson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D (2015) Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194: 2309–2318
24. Dignat-George F, Boulanger CM (2011) The many faces of endo-
25. Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel M, Moita LF, Ther Y, Raposo G (2013) Analysis of ESCRT functions in exosome biogenesis, composition and secre-
26. Pasquet JM, Dachary-Prigent J, Nurden AT (1996) Calcium influx –
27. Van Niel G, Charrin S, Simoes S, Romao M, Rochel P, Manel N, Moita LF, Ther Y, Raposo G (2013) Analysis of ESCRT functions in exosome biogenesis, composition and secre-
28. Van Niel G, Charrin S, Simoes S, Romao M, Rochel P, Manel N, Moita LF, Ther Y, Raposo G (2013) Analysis of ESCRT functions in exosome biogenesis, composition and secre-
29. Pasquet JM, Dachary-Prigent J, Nurden AT (1996) Calcium influx –
30. Hartwig JH, Chambers KA, Stossel TP (1989) Association of –
31. Hartwig JH, Chambers KA, Stossel TP (1989) Association of –
32. Pasquet JM, Dachary-Prigent J, Nurden AT (1996) Calcium influx –
33. Hartwig JH, Chambers KA, Stossel TP (1989) Association of –
34. Hartwig JH, Chambers KA, Stossel TP (1989) Association of –
35. Hartwig JH, Chambers KA, Stossel TP (1989) Association of –
36. Hartwig JH, Chambers KA, Stossel TP (1989) Association of –
37. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
38. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
39. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
40. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
41. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
42. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
43. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
44. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
45. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
46. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
47. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
48. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
49. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
50. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
51. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
52. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
53. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
54. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
55. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
56. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
57. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
58. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
59. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
60. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
61. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
62. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
63. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
64. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
65. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
66. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
67. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
68. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
69. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
70. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
71. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
72. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
73. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
74. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
75. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
76. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
77. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
78. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
79. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
80. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
81. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
82. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
83. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
84. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
85. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
86. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
87. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
88. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
89. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
90. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
91. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
92. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
93. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
94. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
95. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
96. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
97. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
98. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
99. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
100. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
101. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
102. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, –
53. Robert S, Lacroix R, Poncelet P, Harhouri K, Bourkhi T, Judicone C, Wischhusen J, Arnaud L, Dignat-George F (2012) High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles—brief report. Arterioscler Thromb Vasc Biol 32:1054–1058

54. Dragovic RA, Gardiner C, Brooks AS, Tanneta DS, Ferguson DJ, Hole P, Carr B, Redman CW, Harris AL, Dobson PJ, Harrison P, Sargent IL (2011) Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine 7:780–788

55. Lawrie AS, Albanyan A, Cardigan RA, Mackie IJ, Harrison P, Judicone C, Wischhusen J, Arnaud L, Dignat-George F (2012) High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles—brief report. Arterioscler Thromb Vasc Biol 32:1054–1058

56. Witwer KW, Buzas EI, Bemis LT, Bora A, Lasser C, Lotvall J, Sharma S, Rasool HI, Palanisamy V, Mathisen C, Schmidt M, Liu J, Butte MJ (2012) Single molecule labeling of an atomic force microscope cantilever tip. Appl Phys Lett 101:163705

57. Van der Pol E, Coumans F, Varga Z, Krumrey M, Nieuwland R (2009) Microparticle sizing by dynamic light scattering in frozen plasma. Vox Sang 96:206–212

58. Momen-Heravi F, Balaj L, Alian S, Tigges J, Toxavidis V, Choi DS, Kim DK, Kim YK, Gho YS (2015) Proteomics of ex-59. Sharma S, Rasool HI, Palanisamy V, Mathisen C, Schmidt M, Liu J, Butte MJ (2012) Single molecule labeling of an atomic force microscope cantilever tip. Appl Phys Lett 101:163705

60. Witwer KW, Buzas EI, Bemis LT, Bora A, Lasser C, Lotvall J, Sharma S, Rasool HI, Palanisamy V, Mathisen C, Schmidt M, Liu J, Butte MJ (2012) Single molecule labeling of an atomic force microscope cantilever tip. Appl Phys Lett 101:163705

61. Van der Pol E, Coumans F, Varga Z, Krumrey M, Nieuwland R (2009) Microparticle sizing by dynamic light scattering in frozen plasma. Vox Sang 96:206–212

62. Choi DS, Kim DK, Kim YK, Gho YS (2015) Proteomics of extracellular vesicles: exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 12:1182–1192

63. Liu J, Butte MJ (2012) Single molecule labeling of an atomic force microscope cantilever tip. Appl Phys Lett 101:163705

64. Sharma S, Rasool HI, Palanisamy V, Mathisen C, Schmidt M, Liu J, Butte MJ (2012) Single molecule labeling of an atomic force microscope cantilever tip. Appl Phys Lett 101:163705

65. Jacobsson J, Eggertsson B, Stenberg B, Indahl U, Norrby M, Nordenfelt L (2009) Nanoparticle-based flow cytometry: an alternative technique for the detection of exosomes. J Immunol Methods 345:95–101

66. Van der Pol E, van Gemert MJ, Sturk A, Nieuwland R, van der Linden M (2013) Innovation in detection of microparticles and exosomes. J Thromb Haemost 11:36–45

67. Choi DS, Kim DK, Kim YK, Gho YS (2015) Proteomics of extracellular vesicles: exosomes and microvesicles. Mass Spectrom Rev 34:474–490

68. Thery C, Amigorena S, Raposo G, Clayton A (2006) Isolation and selection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. https://doi.org/10.3402/jev.v30i25.20360

69. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J (2008) Intercellular transfer of the oncogenic receptor EGFRVI by microvesicles derived from tumour cells. Nat Cell Biol 10:619–624

70. Mammoto A, Estrov Z, Tsudo M, Xie Y, Ichinose T, Takai Y, Kishimoto T, Caplan AI (2007) A cell-free vesicle transfer system for the spread of morphogens through epithelia. Cell 106:793–805

71. Wahjiahwi J, Khamayseh N, Al-Abed F, Raja S, Al-Hashim M, Al-Mazri H, Al-Abdulaziz A, Al-Bahyar S, Al-Mijbel S, Al-Nowais A, Al-Othman A, Al-Hashim M, Al-Mazri H, Al-Abdulaziz A, Al-Hashim M (2009) Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine 5:191–199

72. Janowska-Wieczorek A, Majka M, Wischhusen J, Arnaud L, Dignat-George F (2012) High-resolution characterization of nanoparticle exosomes in human saliva, using correlation AFM, FESEM, and force spectroscopy. ACS Nano 4:1921–1926

73. Wittwer KW, Buzas EL, Bemis LT, Bora A, Lasser C, Lotvall J, Nolte-’t Hoen EN, Piper MG, Sivaraman S, Skog J, Thery C, Wauben MH, Hochberg F (2013) Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. https://doi.org/10.3402/jev.v30i25.20360

74. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Milosevic J, Tkacheva OA, Divoto SJ, Jordan R, Lyons-Weiler JL, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J (2008) Intercellular transfer of the oncogenic receptor EGFRVI by microvesicles derived from tumour cells. Nat Cell Biol 10:619–624

75. Mack M, Kleinschmidt A, Bruhl H, Klier C, Nelson PJ, Cihak J, Plachy J, Stangassinger M, Erelle V, Schlundorf D (2000) Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 6:769–775

76. Rozmyslowicz T, Majka M, Kijowski J, Murphy SL, Conover DO, Ponce M, Ratyczak J, Gaulton GN, Ratyczak MZ (2003) Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 17:33–42

77. Street JM, Birkhoff W, Menzies RI, Webb DJ, Bailey MA, Dear JW (2011) Exosomal transmission of functional aquaporin 2 in kidney cortical collecting duct cells. J Physiol 589:619–6127

78. Meckes DG Jr, Raab-Traub N (2011) Microvesicles and viral infection. J Virol 85:12844–12854

79. Barry OP, Pratico D, Lawson JA, FitzGerald GA (1997) Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 99:2118–2127

80. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J (2008) Intercellular transfer of the oncogenic receptor EGFRVI by microvesicles derived from tumour cells. Nat Cell Biol 10:619–624

81. Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, Morando L, Busca A, Falda M, Bussolati B, Tetta C, Camussi G (2009) Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 20:1053–1067

82. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Milosevic J, Tkacheva OA, Divoto SJ, Jordan R, Lyons-Weiler JL, Watkins SC, Morelli AE (2012) Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119:756–766

83. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Milosevic J, Tkacheva OA, Divoto SJ, Jordan R, Lyons-Weiler JL, Watkins SC, Morelli AE (2012) Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119:756–766

84. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Milosevic J, Tkacheva OA, Divoto SJ, Jordan R, Lyons-Weiler JL, Watkins SC, Morelli AE (2012) Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119:756–766

85. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Milosevic J, Tkacheva OA, Divoto SJ, Jordan R, Lyons-Weiler JL, Watkins SC, Morelli AE (2012) Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119:756–766

86. Mittelbrunn M, Gutierrez-Vazquez C, Villarroela-Beltr C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, Bernad A, Sanchez-Madrid F (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2:282. https://doi.org/10.1038/ncomms1285

87. Pegtel DM, Cosmopolous K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Grijil TD, Wurdinger T, Middeldorp JM (2010) Functional delivery of viral
miRNAs via exosomes. Proc Natl Acad Sci U S A 107:6328–6333
86. Gracia T, Wang X, Su Y, Norgett EE, Williams TL, Moreno P, Micklem G, Karet Frankel FE (2017) Urinary exosomes contain microRNAs capable of paracrine modulation of tubular transporters in kidney. Sci Rep 7:40601
87. Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, Seraf MC, Round JL, Ward DM, O’Connell RM (2015) Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun 6:7321
88. Cantaluppi V, Medica D, Mannari C, Stiacchini G, Figliolini F, Dellepiane S, Quercia AD, Migliori P, Panichi V, Giovannini L, Bruno S, Tetta C, Biancone L, Camussi G (2015) Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis. Nephrol Dial Transplant 30:410–422
89. Lotvall J, Valadi H (2007) Cell to cell signalling via exosomes through esRNA. Cell Adhes Migr 1:156–158
90. Iida K, Whitlow MB, Nussenzweig V (1991) Membrane vesiculation protects erythrocytes from destruction by complement. J Immunol 147:2638–2642
91. Abid Hussein MN, Niewland R, Hau CM, Evers LM, Meesters EW, Sturk A (2005) Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost 3:888–896
92. Abid Hussein MN, Boing AN, Sturk A, Hau CM, Niewland R (2007) Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 98:1096–1107
93. Gupta KH, Goldufsky JW, Wood SJ, Tardi NJ, Moorthy GS, Gilbert DZ, Zayas JP, Hahn E, Altintas MM, Reiser J, Shahfikani SH (2017) Apoptosis and compensatory proliferation signaling are coupled by CrkI-containing microvesicles. Dev Cell 41:674–684; e675
94. Bussolati B, Camussi G (2017) Renal injury: early apoptotic extracellular vesicles in injury and repair. Nat Rev Nephrol 13:523–524
95. Satta N, Toti F, Feugeas O, Bobhot A, Dachary-Prigent J, Eschwege V, Hedman H, Freyssinet JM (1994) Membrane vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 153:3245–3255
96. Owens AP 3rd, Mackman N (2017) Microparticles in hemostasis and thrombosis. Circ Res 108:1284–1297
97. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR (1999) Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylinositol-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 10:201–210
98. Combes V, Simon AC, Cloarec O, Amouroux D, Camoin L, Sabatier E, Schorey C (2010) Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 123:1603–1611
99. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev TM, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y (2016) Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur J Immunol 46:770–782
100. Soleti R, Bennameur T, Porro C, Panaro MA, Andriantsitohaina R, Martinez MC (2009) Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors. Carcinogenesis 30:580–588
101. Tarabotti G, D’Ascanzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V (2002) Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MMP-14 as membrane vesicle-associated component by endothelial cells. Am J Pathol 160:673–680
102. Martinez MC, Andriantsitohaina R (2011) Microparticles in angiogenesis: therapeutic potential. Circ Res 109:110–119
120. Kim JW, Wieckowski E, Taylor DD, Reichter TE, Watkins S, Whiteside TL (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11:1010–1020

121. Pap E (2011) The role of microvesicles in malignancies. Adv Exp Med Biol 714:183–199

122. Mesri M, Altiere DC (1999) Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 274:23111–23118

123. Gasser O, Schifferli JA (2004) Activated polymorphonuclear neutrophils disseminate anti-inflammatory microvesicles by ectocytosis. Blood 104:2543–2548

124. Distler JH, Huber LC, Gay S, Distler O, Pisetsky DS (2006) Microvesicles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity 39:68–70

125. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Arterioscler Thromb Vasc Biol 25:1512–1518

126. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber TW, Lim BJ, Kim BS, Plotkin MD, Ha SK, Park HC (2014) Circulating plasma factors induce tubular and glomerular alterations with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 33:2540–2546

127. Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Kopp JB, Balow JE, Austin HA 3rd, Yuen PS, Star RA (2008) Urinary exosomes as innate immune effectors. J Am Soc Nephrol 25:2017

128. Karpman D, Ståhl AL, Arvidsson I (2017) Extracellular vesicles in renal disease. Nat Rev Nephrol 13:545–562

129. Gildea JJ, Seaton JE, Victor KG, Reyes CM, Bigler Wang D, JNK1 signaling pathway. J Biol Chem 274:23111

130. Timar CI, Lorincz AM, Csepanyi-Komi R, Valyi-Nagy A, Nagy M, Mostel FA, Meziani F, Agouni A, Heymes C, Mariano F, Cantaluppi V, Stella M, Romanazzi GM, Assenzio B, Erdbrugger U, Le TH (2016) Extracellular vesicles in renal disorganotropic metastasis. Nature 527:329–335

131. Hiemstra TF, Charles PD, Gracia T, Hester SS, Gatto L, Al-Lamki F, Breckmans RJ, Nieuwland R, Berkhourt J, Romijn FP, Hack CE, Ståhl AL, Arvidsson I (2017) Extracellular vesicles in renal proximal tubule cells to distal tubule and collecting duct fusion. J Cell Physiol 229:1202–1210

132. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11:1010–1020

133. Carbuccia N, Dunham CA, Smithies O, Scherr JF (2006) Microvesicles derived from bone marrow mesenchymal stromal cells. Tissue Eng Part A. https://doi.org/10.1089/ten.TEA.2017.0069

134. Erbbruger U, Le TH (2016) Extracellular vesicles in renal diseases: more than novel biomarkers? J Am Soc Nephrol 27:12–26

135. Elmo Marini MF, Dettori D, Neri F, Proveno P, Ponnatto M, Oliviero S, Tetta C, Quesenberry P, Cantaluppi V, Bruno S, Tapparo M, Collino F, Chiabotto G, Deregibus MC, Soares Lindoso R, Neri F, Khola S, Giunti S, Sen, Quesenberry P, Camussi G (2017) Renal regenerative potential of different extracellular vesicle populations derived from bone marrow mesenchymal stromal cells. Tissue Eng Part B. https://doi.org/10.1089/ten.TEB.2017.0069

136. Choi HY, Moon SJ, Ratliff BB, Ahn SH, Jung A, Lee M, Lim BJ, Kim BS, Plotkin MD, Ha SK, Park HC (2014) Microvesicles from kidney-derived mesenchymal stem cells act as carriers of proangiogenic signals and contribute to recovery from acute kidney injury. PLoS One 9:e87583

137. Charbonneau P, Paillard M (2003) Urinary measurement of Na+/H+ exchanger isofrom 3 (NHE3) protein as a new marker of tubule injury in critically ill patients with ARF. Am J Kidney Dis 42:497–506

138. Zhou H, Turowski T, Aponte A, Yuen PS, Hoffert JD, Yasuda H, Hu X, Chawla L, Shen RF, Knepper MA, Star RA (2006) Exosomal fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 70:1847–1857

139. Chen HH, Lai PF, Lan YF, Cheng CF, Zhong WB, Lin YF, Chen TW, Lin H (2014) Exosomal ATPF3 RNA attenuates pro-inflammatory gene MCP-1 transcription in renal ischemia-reperfusion. J Cell Physiol 229:1202–1211

140. Zhou H, Cheruvunkay A, Hu X, Matsumoto T, Hiramatsu N, Cho ME, Berger A, Leelahavanichkul A, Doi K, Chawla LS, Illei GG, Kopp JB, Balow JE, Austin HA 3rd, Yuen PS, Star RA (2008)
Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int 74:613–621

152. Daniel L, Fakhouri F, Joly D, Mouthon L, Nusbaum P, Grunfeld JP, Schifferli J, Guillevin L, Lesavre P, Halbwachs-Mecarelli L (2006) Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 69: 1416–1423

153. Burton JO, Hamali HA, Singh R, Abbasion R, Parsons R, Patel AK, Goodall AH, Brunskill NJ (2013) Elevated levels of procoagulant plasma microparticles in dialysis patients. PLoS One 8:e27663

154. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Aikita T, Nihei H (2002) Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 62:1757–1763

155. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM (2005) Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 16: 3381–3388

156. Trappenburg MC, van Schilfgaarde M, Frerichs FC, Sprook HM, ten Cate H, de Fijter CW, Terpstra WE, Leyte A (2012) Chronic renal failure is accompanied by endothelial activation and a large increase in microparticle numbers with reduced procoagulant capacity. Nephrol Dial Transplant 27:1446–1453

157. Boulanger CM, Amabile N, Guerin AP, Pannier B, Leroyer AS, Mallat CN, Tedgui A, London GM (2007) In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension 49:902–908

158. Amabile N, Guerin AP, Tedgui A, Boulanger CM, London GM (2012) Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant 27:1873–1880

159. Lv LL, Cao YH, Ni HF, Xu M, Liu D, Liu H, Chen PS, Liu BC (2013) MiR-146a in urinary microvesicle as biomarker of renal fibrosis. Am J Physiol Ren Physiol 305:F1220–F1227

160. Lv LL, Cao YH, Pan MM, Liu H, Tang RN, Ma KL, Chen PS, Liu BC (2014) CD2AP mRNA in urinary exosome as biomarker of kidney disease. Clin Chim Acta 428:26–31

161. Stähäl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydeil KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111:5307–5315

162. Kelton JG, Warkentin TE, Hayward CP, Murphy WG, Moore JC (1992) Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. Blood 80: 2246–2251

163. Tati R, Kristoffersson AC, Stähäl AL, Rebetz J, Wang L, Licht C, Mott O, Karpman D (2013) Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 191:2184–2193

164. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS (2003) Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 123:896–902

165. Brogan PA, Shah V, Brachet C, Harnden A, Mant D, Klein N, Dillon MJ (2004) Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 50:927–936

166. Clarke LA, Hong Y, Eleutheriou D, Shah V, Arrigoni F, Klein NJ, Brogan PA (2010) Endothelial injury and repair in systemic vasculitis of the young. Arthritis Rheum 62:1770–1780

167. Hong Y, Eleutheriou D, Hussain AA, Price-Kuehne FE, Savage CO, Jayne D, Little MA, Salama AD, Klein NJ, Brogan PA (2012) Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol 23:49–62

168. Gasser O, Hess C, Miot S, Deon C, Sanchez JC, Schifferli JA (2003) Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. Exp Cell Res 285:243–257

169. Huang YM, Wang H, Wang C, Chen M, Zhao MH (2015) Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol 67:2780–2790

170. Eleftheriou D, Hong Y, Klein NJ, Brogan PA (2011) Thromboembolic disease in systemic vasculitis is associated with enhanced microparticle-mediated thrombin generation. J Thromb Haemost 9:1864–1867

171. Salih M, Zeise R, Hoorn EJ (2014) Urinary extracellular vesicles and the kidney: biomarkers and beyond. J Am Physiol Ren Physiol 306:F1251–F1259

172. Duan ZY, Cai GY, Bu R, Lu Y, Hou K, Chen XM (2014) Selection of urinary sediment miRNAs as specific biomarkers of IgA nephropathy. Sci Rep 6:23498

173. Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC (2011) Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers 30:171–179

174. Moon PG, Lee JE, You S, Kim TK, Cho JH, Kim IS, Kwon TH, Kim CD, Park SH, Hwang D, Kim YL, Baek MC (2011) Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 11:2459–2475

175. Gao C, Xie R, Yu C, Wang Q, Shi F, Yao C, Xie R, Zhou J, Gilbert GE, Shi J (2012) Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb Haemost 107:681–689

176. Hogan MC, Johnson KL, Zenka RM, Charlesworth MC, Madden BJ, Mahoney DW, Gurng AL, Huang BQ, Leontovich AA, Nesbit LL, Bakeberg JL, McCormick DJ, Bergen HR, Ward CJ (2014) Subfractionation, characterization, and in-depth proteomic analysis of glomerular mesangial vesicles in human kidney. Kidney Int 85:1225–1237

177. Zhou H, Kajiyama H, Tsuji T, Hu X, Leelahavanichkul A, Vento S, Frank R, Kopp JB, Trauchtman H, Star RA, Yuen PS (2013) Urinary exosomal Wilms’ tumor-1 as a potential biomarker for podocyte injury. Am J Physiol Ren Physiol 305:F553–F559

178. Lee H, Han KH, Lee SE, Kim SH, Kang HG, Cheong HI (2012) Urinary exosomal WT1 in childhood nephrotic syndrome. Pediatr Nephrol 27:317–320

179. Rood IM, Merchant ML, Wilkey DW, Zhang T, Zabrouskov V, van der Vlag J, Dijkman HB, Willemsen BK, Wetzels JF, Klein JB, Deegens JK (2015) Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy. Proteomics 15:3722–3730

180. Hara M, Yanagihara T, Kihara I, Higashi K, Fujimoto K, Kajita T (2005) Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol 16:408–416

181. Woei AJFJ, van der Starre WE, Tesselaar ME, Garcia Rodriguez P, van Nieuwkoop C, hoekstra RM, Bertina RM, van Dissel JT, Osanto S (2014) Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. Exp Cell Res 285:243–257

182. Pisitkun T, Shen RF, Knepper MA (2004) Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 101:13368–13373
183. Gonzales PA, Pistikun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, Wang NS, Knepper MA (2009) Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol 20:363–379

184. Joo KW, Lee JW, Jang HR, Heo NJ, Jeon US, Oh YK, Lim CS, Na KY, Kim J, Cheong HI, Han JS (2007) Reduced urinary excretion of thiourea-sensitive Na-Cl cotransporter in Gitelman syndrome: preliminary data. Am J Kidney Dis 50:765–773

185. Ben-Dov IZ, Tan YC, Morozov P, Wilson PD, Rennert H, Hogan MC, Manganelli L, Woollard JR, Masyuk AI, Masyuk TV, Tammachote R, Huang BQ, Leontovich AA, Beito TG, Madden BJ, Charlesworth MC, Torres VE, LaRusso NF, Harris PC, Ward CJ (2009) Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol 20:278–288

186. Hogan MC, Bakeberg JL, Gagninullin VG, Irazabal MV, Harmon AJ, Lieske JC, Charlesworth MC, Johnson KL, Madden BJ, Zenga RM, McCormick DJ, Sundsback JL, Heyer CM, Torres VE, Harris PC, Ward CJ (2015) Identification of biomarkers for PKD1 using urinary exosomes. J Am Soc Nephrol 26:1661–1670

187. Hogan MC, Manganeli L, Woollard JR, Masyuk AI, Masyuk TV, Tammachote R, Huang BQ, Leontovich AA, Beito TG, Madden BJ, Charlesworth MC, Torres VE, LaRusso NF, Harris PC, Ward CJ (2009) Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol 20:278–288

188. Wang JM, Su C, Wang Y, Huang YJ, Yang Z, Chen L, Wu F, Xu SY, Tao J (2009) Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients. J Hum Hypertens 23:307–315

189. Huang PH, Huang SS, Chen YH, Lin CP, Chiang KH, Chen JS, Tsai HY, Lin FY, Chen JW, Lin SJ (2010) Increased circulating CD31+ annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 28:1655–1665

190. Kwon SH, Woollard JR, Saad A, Garovic VD, Zand L, Jordan KL, Testor SC, Lerman LO (2016) Elevated urinary podocyte-derived extracellular microvesicles in renovascular hypertensive patients. Nephrol Dial Transplant 32:800–807

191. Al-Massarani G, Vacher-Coponat H, Paul P, Amaud L, Loundou A, Robert S, Moal V, Berland Y, Dignat-George F, Camoin-Jau L (2009) Kidney transplantation decreases the level and procoagulant activity of circulating microparticles. Am J Transplant 9:550–557

192. Montealvaco A, Shufesky WJ, Stolz DB, Sullivan MG, Wang Z, Divito SJ, Pawpworth GD, Watkins SC, Robbins PD, Larregina AT, Morelli AE (2008) Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J Immunol 180:3081–3090

193. Walker JD, Maier CL, Poier JS (2009) Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes. J Immunol 182:1548–1559

194. Campellik A, Gerossier E, Jin J, Tsakiris D, Dickenmann M, Sadallah S, Sufferleti JA, Zecher D (2015) Mechanism of platelet activation and hypercoagulability by antithymocyte globulins (ATG). Am J Transplant 15:2588–2601

195. Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM (2013) Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol 24:1849–1862

196. Dimuccio V, Ranghino A, Pratico Barbato L, Fop F, Biancone L, Camussi G, Bussolati B (2014) Urinary CD133+ extracellular vesicles are decreased in kidney transplanted patients with slow graft function and vascular damage. PLoS One 9:e104490

197. Pisitkun T, Gandolfo MT, Das S, Knepper MA, Bagnasco SM (2012) Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation. Proteomics Clin Appl 6:268–278

198. Alvarez S, Suazo C, Boltsansky A, Uris M, Carvajal D, Innocenti G, Vukusich A, Hurtado M, Villanueva S, Carreno JE, Rogelio A, Irrazabal CE (2013) Urinary exosomes as a source of kidney dysfunction biomarker in renal transplantation. Transplant Proc 45:3719–3723

199. Peake PW, Pianta TJ, Succar L, Fernando M, Pugh DJ, McNamara K, Endre ZH (2014) A comparison of the ability of levels of urinary biomarker proteins and exosomal mRNA to predict outcomes after renal transplantation. PLoS One 9:e89844

200. Sonoda H, Yokota-Ikeda N, Oshikawa S, Kanno Y, Yoshinaka K, Uchida K, Ueda Y, Kiyimi K, Uezono S, Ueda A, Ito, K, Ikeda M (2009) Decreased abundance of urinary exosomal aquaporin-1 in renal ischemia-reperfusion injury. Am J Physiol Ren Physiol 297: F1006–F1016

201. Meehan SM, Limsrichamrern S, Manaligod JR, Junsanto T, Josephson MA, Thistlethwaite JR, Haas M (2003) Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol 34:533–540

202. Nielsen CT, Ostergaard O, Johnsen C, Jacobsen S, Heegaard NH (2011) Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum 63:3067–3077

203. Nielsen CT, Ostergaard O, Stener L, Iversen LV, Truedsson L, Gullstrand B, Jacobsen S, Heegaard NH (2012) Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum 64:1227–1236

204. Pereira J, Alfaro G, Guyocoolea M, Quiroga T, Ocqueteau M, Massardo L, Perez C, Saez C, Panes O, Matus V, Mezzano D (2006) Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 95:94–99

205. Sole C, Cortes-Hernandez J, Felip ML, Vidal M, Ordí-Ros J (2015) miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. Nephrol Dial Transplant 30:1488–1496

206. Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Mool V, Sammarco M, Sampol J (2004) Endothelial microparticles: a potential contributor to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 91:665–673

207. Pericelous C, Giles I, Rahman A (2009) Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? Lupus 18:671–675

208. Ridger VC, Boulanger CM, Angelillo-Scherrer A, Badimon L, Blanc-Brude O, Bochaton-Piallat ML et al (2017) Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Thromb Haemost 117: 1296–1316

209. Lakhker AJ, Sims EK (2015) Minireview: emerging roles for extracellular vesicles in diabetes and related metabolic disorders. Mol Endocrinol 29:1535–1548

210. Sabatier F, Darmon P, Hugel B, Combes V, Sammarco M, Velut JG, Arnoux D, Charpott P, Freysinet JM, Oliver C, Sampol J, Dignat-George F (2002) Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 51: 2840–2845

211. Omoto S, Nomura S, Shouzu A, Nishikawa M, Fukuhara S, Iwasaka T (2002) Detection of monocyte-derived microparticles...
in patients with type II diabetes mellitus. Diabetologia 45:550–555
214. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK (2002) Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 106:2442–2447
215. Chen Y, Feng B, Li X, Ni Y, Luo Y (2012) Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J Clin Hypertens (Greenwich) 14:455–460
216. Zubiri I, Posada-Ayala M, Benito-Martin A, Maroto AS, Martin-Chana P, de la Cuesta F, Gonzalez-Calero L, Bardejas MG, Fernandez-Fernandez B, Ortiz A, Vivanco F, Alvarez-Llamas G (2015) Kidney tissue proteomics reveals reguculin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. Transf Res 166:474–484; e474
217. Barutta F, Tricarico M, Corbelli A, Annaratone L, Pinach S, Grimaldi S, Bruno G, Cinimo D, Taverna D, Derebbius MC, Rastaldi MP, Perin PC, Gruden G (2013) Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One 8:e73798
218. Kalani A, Mohan A, Godbole MM, Bhatai E, Gupta A, Sharma RK, Tiwari S (2013) Wilm’s-tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria. PLoS One 8:e60177
219. Ge S, Hertel B, Ernden SH, Beneke J, Menne J, Haller H, von Vietinghoff S (2012) Microparticle generation and leukocyte death in Shiga toxin-mediated HUS. Nephrol Dial Transplant 27:2447–2457
220. Karpman D, Loos S, Tati R, Arvidsson I (2017) Haemolytic uraemic syndrome. J Intern Med 281:123–148
221. Kahn R, Herwald H, Muller-Esterl W, Schmitt R, Sjoergen AC, Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Jardin M (2016) Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 26:2594–2604
222. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rebe C, Ghiringhelli F (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120:457–471